Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Myotonic Dystrophy Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Myotonic Dystrophy Drugmarket, defines the market attractiveness level of Myotonic Dystrophy Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Myotonic Dystrophy Drug industry, describes the types of Myotonic Dystrophy Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Myotonic Dystrophy Drug market and the development prospects and opportunities of Myotonic Dystrophy Drug industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Myotonic Dystrophy Drug market in Chapter 13.
By Player:
Marina Biotech, Inc
Isis Pharmaceuticals, Inc
F Hoffmann-La Roche Ltd
Genzyme Corporation
Valentia Biopharma SL
BioMarin Pharmaceutical Inc
By Type:
ISIS-DMPKRx
PRO-135
SRT-152
VAL-0411
Others
By End-User:
Hospital
Clinic
Home Use
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Myotonic Dystrophy Drug Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Myotonic Dystrophy Drug Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Myotonic Dystrophy Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Myotonic Dystrophy Drug Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Myotonic Dystrophy Drug Market Analysis and Outlook to 2022
-
7.1 Global Myotonic Dystrophy Drug Consumption (2017-2022)
-
7.2 United States Myotonic Dystrophy Drug Consumption (2017-2022)
-
7.3 Europe Myotonic Dystrophy Drug Consumption (2017-2022)
-
7.4 China Myotonic Dystrophy Drug Consumption (2017-2022)
-
7.5 Japan Myotonic Dystrophy Drug Consumption (2017-2022)
-
7.6 India Myotonic Dystrophy Drug Consumption (2017-2022)
-
7.7 South Korea Myotonic Dystrophy Drug Consumption (2017-2022)
8 Region and Country-wise Myotonic Dystrophy Drug Market Analysis and Outlook to 2028
-
8.1 Global Myotonic Dystrophy Drug Consumption Forecast (2022-2028)
-
8.2 United States Myotonic Dystrophy Drug Consumption Forecast (2022-2028)
-
8.3 Europe Myotonic Dystrophy Drug Consumption Forecast (2022-2028)
-
8.4 China Myotonic Dystrophy Drug Consumption Forecast (2022-2028)
-
8.5 Japan Myotonic Dystrophy Drug Consumption Forecast (2022-2028)
-
8.6 India Myotonic Dystrophy Drug Consumption Forecast (2022-2028)
-
8.7 South Korea Myotonic Dystrophy Drug Consumption Forecast (2022-2028)
9 Global Myotonic Dystrophy Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Myotonic Dystrophy Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global ISIS-DMPKRx Consumption and Growth Rate (2017-2022)
-
9.1.2 Global PRO-135 Consumption and Growth Rate (2017-2022)
-
9.1.3 Global SRT-152 Consumption and Growth Rate (2017-2022)
-
9.1.4 Global VAL-0411 Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Myotonic Dystrophy Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Home Use Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Others Consumption and Growth Rate (2017-2022)
10 Global Myotonic Dystrophy Drug Market Outlook by Types and Applications to 2028
-
10.1 Global Myotonic Dystrophy Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global ISIS-DMPKRx Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global PRO-135 Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global SRT-152 Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global VAL-0411 Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Myotonic Dystrophy Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Home Use Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Myotonic Dystrophy Drug Import and Export Analysis (Top 5 Countries)
-
11.1 Global Myotonic Dystrophy Drug Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Myotonic Dystrophy Drug Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Myotonic Dystrophy Drug Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Myotonic Dystrophy Drug Market Competitive Analysis
-
14.1 Marina Biotech, Inc
-
14.1.1 Marina Biotech, Inc Company Details
-
14.1.2 Marina Biotech, Inc Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Marina Biotech, Inc Myotonic Dystrophy Drug Product and Service
-
14.2 Isis Pharmaceuticals, Inc
-
14.2.1 Isis Pharmaceuticals, Inc Company Details
-
14.2.2 Isis Pharmaceuticals, Inc Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Isis Pharmaceuticals, Inc Myotonic Dystrophy Drug Product and Service
-
14.3 F Hoffmann-La Roche Ltd
-
14.3.1 F Hoffmann-La Roche Ltd Company Details
-
14.3.2 F Hoffmann-La Roche Ltd Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 F Hoffmann-La Roche Ltd Myotonic Dystrophy Drug Product and Service
-
14.4 Genzyme Corporation
-
14.4.1 Genzyme Corporation Company Details
-
14.4.2 Genzyme Corporation Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Genzyme Corporation Myotonic Dystrophy Drug Product and Service
-
14.5 Valentia Biopharma SL
-
14.5.1 Valentia Biopharma SL Company Details
-
14.5.2 Valentia Biopharma SL Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Valentia Biopharma SL Myotonic Dystrophy Drug Product and Service
-
14.6 BioMarin Pharmaceutical Inc
-
14.6.1 BioMarin Pharmaceutical Inc Company Details
-
14.6.2 BioMarin Pharmaceutical Inc Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 BioMarin Pharmaceutical Inc Myotonic Dystrophy Drug Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Myotonic Dystrophy Drug
-
Figure Myotonic Dystrophy Drug Picture
-
Table Global Myotonic Dystrophy Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Myotonic Dystrophy Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Myotonic Dystrophy Drug Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Myotonic Dystrophy Drug Consumption by Country (2017-2022)
-
Figure United States Myotonic Dystrophy Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Myotonic Dystrophy Drug Consumption and Growth Rate (2017-2022)
-
Figure China Myotonic Dystrophy Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Myotonic Dystrophy Drug Consumption and Growth Rate (2017-2022)
-
Figure India Myotonic Dystrophy Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Myotonic Dystrophy Drug Consumption and Growth Rate (2017-2022)
-
Figure Global Myotonic Dystrophy Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Myotonic Dystrophy Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Myotonic Dystrophy Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Myotonic Dystrophy Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Myotonic Dystrophy Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Myotonic Dystrophy Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Myotonic Dystrophy Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global ISIS-DMPKRx Consumption and Growth Rate (2017-2022)
-
Figure Global PRO-135 Consumption and Growth Rate (2017-2022)
-
Figure Global SRT-152 Consumption and Growth Rate (2017-2022)
-
Figure Global VAL-0411 Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Home Use Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global ISIS-DMPKRx Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global PRO-135 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global SRT-152 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global VAL-0411 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Home Use Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Myotonic Dystrophy Drug Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Myotonic Dystrophy Drug Export by Region (Top 5 Countries) (2017-2028)
-
Table Marina Biotech, Inc (Foundation Year, Company Profile and etc.)
-
Table Marina Biotech, Inc Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Marina Biotech, Inc Myotonic Dystrophy Drug Product and Service
-
Table Isis Pharmaceuticals, Inc (Foundation Year, Company Profile and etc.)
-
Table Isis Pharmaceuticals, Inc Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Isis Pharmaceuticals, Inc Myotonic Dystrophy Drug Product and Service
-
Table F Hoffmann-La Roche Ltd (Foundation Year, Company Profile and etc.)
-
Table F Hoffmann-La Roche Ltd Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann-La Roche Ltd Myotonic Dystrophy Drug Product and Service
-
Table Genzyme Corporation (Foundation Year, Company Profile and etc.)
-
Table Genzyme Corporation Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genzyme Corporation Myotonic Dystrophy Drug Product and Service
-
Table Valentia Biopharma SL (Foundation Year, Company Profile and etc.)
-
Table Valentia Biopharma SL Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Valentia Biopharma SL Myotonic Dystrophy Drug Product and Service
-
Table BioMarin Pharmaceutical Inc (Foundation Year, Company Profile and etc.)
-
Table BioMarin Pharmaceutical Inc Myotonic Dystrophy Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table BioMarin Pharmaceutical Inc Myotonic Dystrophy Drug Product and Service
-
